Steffan Ho is Vice President and Head of Translational Oncology at Pfizer in the Global Product Development organization. In this role, he oversees translational and precision medicine strategies that support clinical development across a diverse oncology portfolio.
While at Pfizer he has supported the regulatory approvals of several targeted therapies and companion diagnostic tests benefiting patients with solid tumor and hematologic malignancies.
Prior to joining Pfizer, Dr. Ho was on the faculty of the School of Medicine in the Departments of Pathology and Cellular and Molecular Medicine at the University of California-San Diego as a board-certified pathologist, and later held positions in Discovery and Translational Oncology at Biogen.
Dr. Ho received his B.A. in chemistry and biology from Carleton College and his M.D. and Ph.D. in immunology from the Mayo Clinic. He pursued post-graduate residency training and postdoctoral research at the Stanford University School of Medicine.